CHIMERIC THERAPEUTICS

THE ASX LEADER IN CELL THERAPY

THE CORE-NK PLATFORM

PHASE 1 CLINICAL DATA

MONDAY MARCH 7, 2022

CORE-NK PLATFORM (CHM 0201)

Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform



- A universal, off the shelf, natural killer cell platform technology
- Developed by Dr. David Wald, a clinical scientist at Case Western Reserve University
- Specifically designed to overcome the hurdles often associated with NK cell development, including the ability to produce large numbers of highly active universal donor NK cells that maintain their activity once they're in the body.
- Chimeric exclusive option with a planned licensing and research collaboration with Case Western
- Platform enables near-term development Chimeric therapies for solid tumors and blood cancers



CORE-NK Platform

Positive Phase 1A Clinical Data

COMPELLING EFFICACY IN BLOOD CANCERS

100% Disease Control Rate (DCR) achieved in blood cancer patients (n=3)

100+ day durability in 2 out of 3 patients

Durable Complete Response (CR) achieved with **15+** month ongoing response

PROMISING EFFICACY IN SOLID TUMORS

33% Disease Control Rate (DCR) achieved in solid tumor patients (n=6)

DEMONSTRATED SAFETY

Positive safety profile established with no Graft versus Host Disease (GvHD), Cytokine Release Syndrome or Dose Limiting Toxicities

ESTABLISHED EXPANSION AND PERSISTENCE

Proven robust expansion of universal donor NK cells

Demonstrated **4-week** persistence without exogenous cytokine support

Otegbeye et al. *A Phase I study to determine maximum tolerated dose of ex vivo expanded natural killer cells derived from unrelated, HLA-disparate adult donors.* Transplantation and Cellular Therapy, 2022, ISSN 2666-6367, https://doi.org/10.1016/j.jtct.2022.02.008

CORE-NK PLATFORM

PHASE 1A TRIAL DESIGN

The trial was designed to establish the safety of CORE-NK universal donor NK cells while assessing cell expansion, persistence and anti-tumor activity.

PATIENT ELIGIBILITY



PRIMARY OBJECTIVE:

To demonstrate that escalating doses of the CORE-NK platform could be infused without inducing GvHD or other significant toxicities

SECONDARY OBJECTIVE:

To examine if the lymphocyte depleting regimen would prevent immediate rejection of the HLA-mismatched NK cell product allowing for demonstrable anti-tumor effect

Study Initiation: May 2018

Primary Study Completion: June 2021

CORE-NK PLATFORM

PHASE 1A TRIAL DESIGN

PHASE 1 DOSE ESCALATION



Dosing:

9 patients : 3 Blood Cancers / 6 Solid Tumors



CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS

SAFETY ESTABLISHED ACROSS ALL DOSE LEVELS

All observed events were expected events attributable to the lymphocyte-depleting chemotherapy regimen.

Otegbeye et al. *A Phase I study to determine maximum tolerated dose of ex vivo expanded natural killer cells derived from unrelated, HLA-disparate adult donors.* Transplantation and Cellular Therapy, 2022, ISSN 2666-6367, https://doi.org/10.1016/j.jtct.2022.02.008

CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS

5 OF 9 (56%) PATIENTS EXPERIENCED DISEASE STABILITY INCLUDING ONE COMPLETE REMISSION

Cell Dose	10 x 10^6/kg			25 x 10^6/kg			50 x 10^6/kg		
Patient ID #	#1	#4	#5	#7	#8	#12	#13	#14	#15
Diagnosis	MDS/AML	Colorectal	Colorectal	Colorectal	High-Risk MDS, post-HCT relapse	Myeloid Sarcoma	Colon Cancer	Colon Cancer	Colon Cancer
Metastatic sites	N/A	multiple	lungs	multiple	N/A	N/A	Multiple	Lung	Liver, lungs
Response D28	**Stable**	**Progression**	**Stable**	**Progression**	**Stable**	**Stable**	**Progression**	**Stable**	**Progression**
Response D100	Progression	N/A	Stable	N/A	CRi	Stable	N/A	Progression	N/A

MDS=Myelodysplastic syndromes; AML=Acute myeloid leukemia; mCRC=Metastatic colorectal cancer; CRi=Complete Response with incomplete platelet recovery; SD=Stable Disease; PD=Progressive disease; DCR=Disease Control Rate; CRS=Cytokine release syndrome; GvHD=Graft vs. Host disease.

1. Otegbeye et al, 2022; Transplantation & Cellular Therapy. doi.org/10.1016/jtct.2022.02.008

CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS

100% DISEASE CONTROL IN PATIENTS WITH BLOOD CANCERS

Hematological Malignancies			
Cell Dose	10 x 10^6/kg	25 x 10^6/kg	25 x 10^6/kg
Patient ID #	#1	#8	#12
Diagnosis	MDS/AML	High-Risk MDS, post-HCT relapse	Myeloid Sarcoma
Response D28	**Stable**	**Stable**	**Stable**
Response D100	Progression	CRi	Stable

100% DCR

66%

100-day durability of response

1 CRi

With 15+ month durability of remission

1. Otegbeye et al, 2022; Transplantation & Cellular Therapy. doi.org/10.1016/j.jtct.2022.02.008

CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS

COMPLETE RESPONSE IN HIGH RISK MDS

Case Study: Patient ID #8

Complete response with 15+ months ongoing remission

DIAGNOSIS:	High risk MDS with circulating blasts and high tumor burden
HISTORY:	Progressive disease with prior allogeneic transplant
RESPONSE:	Stable Disease at day 28, Complete Response by day 60
DURABILITY OF RESPONSE:	**Sustained Complete Response at Day 100** Remains in remission 15+ months after receiving consolidation transplant
SAFETY:	No dose limiting toxicities, no cytokine release syndrome, no GvHD

CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS[1]

DISEASE CONTROL IN HEAVILY PRE-TREATED METASTATIC COLORECTAL PATIENTS

Cell Dose	10 x 10^6/kg		25 x 10^6/kg	50 x 10^6/kg		
Patient ID #	#4	#5	#7	#13	#14	#15
Diagnosis	Colorectal	Colorectal	Colorectal	Colon	Colon	Colon
Metastatic sites	Multiple	Lungs	Multiple	Multiple	Lung	Multiple
Response D28	**Progression**	**Stable**	**Progression**	**Progression**	**Stable**	**Progression**
Response D100	N/A	Stable	N/A	N/A	Progression	N/A

33%
DCR

50%
100-day durability of response

1. Otegbeye et al, 2022; Transplantation & Cellular Therapy. doi.org/10.1016/jtct.2022.02.008

CORE-NK PLATFORM (CHM 0201)

DEMONSTRATED EXPANSION AND PERSISTENCE WITH UNIVERSAL DONOR NK CELLS

Universal Donor
(non-HLA matched)
NK cells



Robust Expansion
Demonstrated
(up to 30,000-fold)



28 Day
Persistence
with no GvHD



CORE-NK PLATFORM PHASE 1 CLINICAL TRIAL:

OVERCOMING THE CHALLENGES OF NK CELL DEVELOPMENT

THERAPEUTIC EFFECT IN SOLID TUMORS AND BLOOD CANCERS	**01**	Established anti-tumor effect with responses in blood cancers and solid tumors past day 100 and a complete response in High-Risk MDS
ESTABLISHED SAFETY WITH UNIVERSAL DONOR CELLS	**02**	Demonstrated lack of GvHD allows for donor simplification and delivery of a true universal therapy while enhancing "graft versus tumor" effect
28 DAY PERSISTENCE WITH HIGHER LYMPHODEPLETION DOSE	**03**	Higher lymphodepleting dose prevents immediate host rejection for longer – up to 28 day – cell persistence
ROBUST EXPANSION: MANUFACTURING SUCCESS	**04**	Successful generation of large quantities of CORE-NK cells from one donor, with one 21-day manufacturing run simplifies logistical feasibility and reduces costs
IDENTIFIED OPPORTUNITY TO AMPLIFY THERAPEUTC EFFECT	**05**	Opportunity to enhance anti-tumor activity by increasing the CORE-NK cell dose, providing exogenous cytokine support and promoting tumor bed infiltration

CORE-NK PLATFORM (CHM 0201)

ACCELERATING MULTIPLE DEVELOPMENT PATHS



1. CORE-NK Combination Therapy

Rapid development in combination therapy

2. Next Generation CORE-NK Platform

Further enhancement with next generation technologies

3. CAR-NK Products

Fast-forward development of CAR NK products using our CLTX and CDH17 chimeric antigen receptors

4. Leverage the CORE-NK Platform

Identify collaborations or licensing opportunities to further expand the utilization of the CORE-NK platform

A ROBUST AND ADVANCED CELL THERAPY PORTFOLIO AND PIPELINE



7

Unique Assets

8

Clinical Programs by 2023

10+

Disease Areas

THE ASX LEADER IN CELL THERAPY AND AN EMERGING GLOBAL CELL THERAPY COMPANY

✓ **Innovative & Diversified Portfolio**

7 novel individualized (autologous) T cell and off the shelf (allogeneic) NK cell therapies

✓ **Broad Therapeutic Focus**

Development 10+ types of blood cancers and solid tumors for extensive commercial opportunity

✓ **Extensive Clinical Development**

4 planned clinical programs in 2022 and 8 planned clinical programs by 2023

✓ **Early Positive Signals in Multiple Trials**

Initial positive phase 1 clinical data in GBM and with the CORE-NK platform

✓ **World Renowned Partners**

Research collaborations with world renowned cell therapy centers and scientists

✓ **Industry Leading Experience**

Internal team of experts in successful cell therapy development and commercialization

CHIMERIC THERAPEUTICS

CONTACT INFORMATION

Jennifer Chow
Chief Executive Officer
and Managing Director
Cell: +1 908-723-8387
jchow@chimerictherapeutics.com

Paul Hopper
Executive Chairman
Cell: +61 406 671 515
paulhopper@lifescienceportfolio.com